Broadcom missed revenue estimates in its fiscal Q2 and saw shares plunge 14% after holding its $100 billion AI chip sales forecast for 2026 unchanged. The results highlight softening software sales even as AI revenue more than doubled and is expected to triple in the current quarter.

Hock Tan did not raise the full-year target of $100 billion in AI semiconductor sales for 2026.
Tan said Broadcom would offer "chips only" instead of the complete integrated AI systems it had previously planned to provide.
Tap a lens to see what this story means for you.
Reader-supported · The Brief
Liked this? The Brief brings you the whole day in tech, verified, every morning. Two minutes, free forever.
See what’s happening right now
The Feed runs all day — short, verified briefs the moment they break.
Open the FeedFollow @thecircuitry_
Every story we publish, as it happens. No noise between.
Reader-supported
The Circuitry is a passion project I've always wanted to build, and I love the work behind it.
Running it costs real money. APIs, hosting, time. To keep improving the site and growing this into something useful for everyone, those costs have to be covered.
Any contribution is appreciated. If not, no pressure. Thanks for reading.
Seattle startup funding dropped about 40% in the first half of 2026 while AI money flowed elsewhere, alongside a court loss for Kalshi, Impinj's 10-year Nasdaq milestone, and a local flip-phone detox trial. The developments highlight shifting venture dynamics, legal hurdles for prediction markets, corporate endurance, and growing interest in reducing smartphone reliance.
Repligen will acquire BioLife Solutions for $1.5 billion, merging two longtime providers of tools for cell and gene therapy and biopreservation. The deal values BioLife shares at $31 each and is slated to close in the fourth quarter pending approvals.
BitMEX will close its crypto derivatives exchange in September and has urged users to withdraw funds as soon as possible. The shutdown follows a strategic review and comes after years of regulatory penalties and legal actions against the company and its founders.